Ganglioside (Asialo-GM1, GM1, GM2, GD1a, GD1b, and GQ1b) Antibodies
0051033
Ordering Recommendation
 
Mnemonic
GM1 COMBI
Methodology
Semi-Quantitative Enzyme-Linked Immunosorbent Assay
Performed
Mon, Wed, Fri
Reported
1-4 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Serum separator tube.  
Specimen Preparation
Separate serum from cells ASAP. Transfer 0.3 mL serum to an ARUP Standard Transport Tube. (Min: 0.1 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Room temperature specimens. Plasma, CSF, or other body fluids. Contaminated, heat-inactivated, hemolyzed , severely icteric, or lipemic specimens.  
Remarks
  
Stability
After separation from cells: Ambient: Unacceptable; Refrigerated: 2 weeks; Frozen: 1 year  
Reference Interval
 
 
Test Number Components Reference Interval
 Asialo-​GM1 Antibodies, IgG/IgM 29 IV or less: Negative
30-​50 IV: Equivocal
51-​100 IV: Positive
101 IV or greater: Strong Positive
 GM1 Antibodies, IgG/IgM 29 IV or less: Negative
30-​50 IV: Equivocal
51-​100 IV: Positive
101 IV or greater: Strong Positive
 GM2 Antibodies, IgG/IgM 29 IV or less: Negative
30-​50 IV: Equivocal
51-​100 IV: Positive
101 IV or greater: Strong Positive
 GD1a Antibodies, IgG/IgM 29 IV or less: Negative
30-​50 IV: Equivocal
51-​100 IV: Positive
101 IV or greater: Strong Positive
 GD1b Antibodies, IgG/IgM 29 IV or less: Negative
30-​50 IV: Equivocal
51-​100 IV: Positive
101 IV or greater: Strong Positive
 GQ1b Antibodies, IgG/IgM 29 IV or less: Negative
30-​50 IV: Equivocal
51-​100 IV: Positive
101 IV or greater: Strong Positive
Interpretive Data
Ganglioside antibodies are associated with diverse peripheral neuropathies. Elevated antibody levels to ganglioside-monosialic acid (GM1) and the neutral glycolipid, asialo-GM1 are associated with motor or sensorimotor neuropathies, particularly multifocal motor neuropathy. Anti-GM1 may occur as IgM (polyclonal or monoclonal) or IgG antibodies. These antibodies may also be found in patients with diverse connective tissue diseases as well as normal individuals. GD1a antibodies are associated with different variants of Guillain-Barre syndrome (GBS) particularly acute motor axonal neuropathy while GD1b antibodies are predominantly found in sensory ataxic neuropathy syndrome. Anti-GQ1b antibodies are seen in more than 80% of patients with Miller-Fisher syndrome and may be elevated in GBS patients with ophthalmoplegia. The role of isolated anti-GM2 antibodies is unknown. These tests by themselves are not diagnostic and should be used in conjunction with other clinical parameters to confirm disease.

See Compliance Statement D: www.aruplab.com/CS
Statement D: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
 
CPT Code(s)
83516 x6
Components
Component Test Code*Component Chart NameLOINC
0051034Asialo-GM1 Antibodies, IgG/IgM44737-5
0051035GM1 Antibodies, IgG/IgM63244-8
0051036GM2 Antibodies, IgG/IgM63249-7
0051037GD1a Antibodies, IgG/IgM48656-3
0051038GD1b Antibodies, IgG/IgM26870-6
0051039GQ1b Antibodies, IgG/IgM31674-5
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Anti-GM Antibodies
  • Asialo-GM1 Antibodies, IgG/IgM
  • Asialo-GM1, GM1, GD1b, GQ1b IgG and IgM
  • Ganglioside Antibodies
  • Ganglioside Abs IgG and IgM
  • GM1, GM2, GD1a, GD1b, GQ1b IgG/IgM